drugset / Trial / NCT02595749

Effects of Intranasal Oxytocin on Cigarette Smoking

NCT02595749

Phase 4 Completed 83 enrolled University of Southern California
RandomizedCrossoverDouble-blindBasic science

Summary

Socioemotional processing dysfunctions (i.e., disruptions in affective, cognitive, and neural processes that encode, interpret, and respond to socially and emotionally relevant stimuli) have been implicated in tobacco smoking and relapse, however this potential target for medication development has not been systematically examined. Evidence from animal and human laboratories indicate that administration of intranasal oxytocin enhances socioemotional processing and may be efficacious for the treatment of drug addiction, including nicotine dependence. In order to evaluate the potential efficacy of intranasal oxytocin for smoking cessation, this laboratory-based proposal will examine whether intranasal oxytocin attenuates smoking lapse, nicotine withdrawal, and socioemotional processing disruptions in regular smokers following overnight abstinence.

Timeline

Start
2016-07
Primary completion
2019-07
Completion
2019-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxytocin Peptide 40 iu Intranasal

Indications